Search research articles
Contact Us
Filters
Showing results (121-130 of 174) with videos related to
Page
of 18
Sort By:
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
JAMA Oncology
|
November 15, 2019
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care
Alexander Penson, Niedzica Camacho, Youyun Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Cancer Discovery
|
March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer
Emily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
Page
of 18
Search research articles
Search
Showing results (121-130 of 174) with videos related to
Sort By:
Page
of 18
Gynecologic Oncology
|
July 30, 2020
Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial
Ana Oaknin, Claire F Friedman, Lynda D Roman, et al.
The New England Journal of Medicine
|
August 20, 2015
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M Hyman, Igor Puzanov, Vivek Subbiah, et al.
JAMA Oncology
|
November 15, 2019
Development of Genome-Derived Tumor Type Prediction to Inform Clinical Cancer Care
Alexander Penson, Niedzica Camacho, Youyun Zheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Diverse <i>BRCA1</i> and <i>BRCA2</i> Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino-Méndez, Ino de Bruijn, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 2, 2015
Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer
Rachel N Grisham, Brooke E Sylvester, Helen Won, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 4, 2024
Trastuzumab and Pertuzumab in Patients with Non-Breast/Gastroesophageal HER2-Amplified Tumors: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol J
Roisin M Connolly, Victoria Wang, David M Hyman, et al.
The Journal of Clinical Investigation
|
June 20, 2018
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies
Justin Taylor, Dean Pavlick, Akihide Yoshimi, et al.
Cancer Discovery
|
March 17, 2019
Patient-Driven Discovery, Therapeutic Targeting, and Post-Clinical Validation of a Novel <i>AKT1</i> Fusion-Driven Cancer
Emily K Slotkin, Daniel Diolaiti, Neerav N Shukla, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2018
Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
Bob T Li, Ronglai Shen, Darren Buonocore, et al.
Page
of 18